SIGA
SIGA Technologies, Inc. (NASDAQ)
Healthcare — Drug Manufacturers - Specialty & Generic
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.
None
$3.39
$-0.19 (-5.31%)
Sign in to add SIGA to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $270.76M |
| P/E Ratio (TTM) | 13.48 |
| Forward P/E | 3.60 |
| EPS (TTM) | $0.28 |
| Dividend Yield | - |
| Profit Margin | 21.58% |
| Revenue Growth | -11.30% |
| ROE | 11.00% |
| Debt/Equity | 0.40 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 23.9 |
| Beta | 0.85 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $9.62 |
| 52-Week Low | $3.56 |
| 50-Day Avg | $4.40 |
| 200-Day Avg | $6.12 |
| Avg Volume | 532.8K |
| Volume | 469.1K |
Performance Analysis
BULLISHSIGA shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($3.56), which could present a value opportunity.
+
RSI at 23.9 signals oversold conditions — a bounce may be ahead.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
P/E of 13.5 suggests the stock may be undervalued.
-
Revenue declined 11.3% year-over-year.
+
Healthy profit margin of 21.6%.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:31 UTC
Back to Screener Export Report